120 related articles for article (PubMed ID: 8752169)
1. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
3. Modulation of cisplatin resistance in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
[TBL] [Abstract][Full Text] [Related]
4. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Jones JA; Albright KD; Christen RD; Howell SB; McClay EF
Cancer Res; 1997 Jul; 57(13):2657-60. PubMed ID: 9205073
[TBL] [Abstract][Full Text] [Related]
5. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
7. delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
McClay EF; Winski PJ; Jones JA; Jennerette J; Gattoni-Celli S
Cancer Res; 1996 Sep; 56(17):3866-9. PubMed ID: 8752147
[TBL] [Abstract][Full Text] [Related]
8. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
9. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
[TBL] [Abstract][Full Text] [Related]
10. Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen?
Mohammed MQ; Photiou A; Shah P; Retsas S
Anticancer Res; 1995; 15(4):1319-26. PubMed ID: 7654015
[TBL] [Abstract][Full Text] [Related]
11. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
12. Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor.
Wen L; Hong D; Yanyin W; Mingyue Z; Baohua L
Arch Gynecol Obstet; 2013 May; 287(5):997-1004. PubMed ID: 23212665
[TBL] [Abstract][Full Text] [Related]
13. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
14. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
16. The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines.
Kim MJ; Lee JH; Kim YK; Myoung H; Yun PY
Cancer Lett; 2007 Jan; 245(1-2):284-92. PubMed ID: 16513256
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Int J Cancer; 1993 Dec; 55(6):1018-22. PubMed ID: 8253520
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
19. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
20. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
